APPLY TO SPEEDRUN
← Insitro
Insitro · Hiring

Senior Director, Project & Portfolio Management

South San Francisco, CAHybridFull Time

The Opportunity

The unprecedented convergence of multi-modal data, advanced disease modeling, and computational power is revolutionizing drug discovery. insitro is harnessing this moment to redefine how medicines are developed for complex diseases. Our AI/ML-enabled platforms integrate and scale data to rapidly discover novel biological insights to redefine complex diseases and identify new targets and drugs. To enable this vision we are seeking a Senior Director of Project & Portfolio Management (PPM) who will build an AI-forward PPM organization that will partner with Therapeutic Area, Operations, Clinical and Business Development teams to discover and advance a high-value portfolio of exciting drug candidates into the clinic for neurological, ophthalmological and metabolic indications.

Reporting into the CSO, you and your staff will partner with project team leaders in developing rightsized project strategies and create successful team environments to foster high performance and rapid advancement. You will develop and execute high quality integrated project plans with clear timelines spanning research, discovery, clinical development, software engineering, and data science/machine learning. As the leader of PPM you will partner with Compute, Operations and Finance colleagues in establishing agentic AI project management, decision and resource allocation tools and methodologies across our portfolio to support critical initiatives.

This role will be hybrid, coming onsite to our South San Francisco headquarters with three days per week in the office.

 

About You

Nice to Have

Your Ways of Working and Alignment with insitro Values

 

Compensation & Benefits at insitro

Our target starting salary for successful US-based applicants for this role is $264,000 - $298,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.

This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.

In addition, insitro also provides our employees:

insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.

We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.

Please be aware of recruitment scams: we never request payments, all recruitment communications are from @insitro.com, and if in doubt, contact us at info@insitro.com.

#LI-Hybrid

About insitro

insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.

Interested in This Role?

Apply at Insitro

You'll head to Insitro's own careers page.